Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor–Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)

PURPOSE: There is no research evidence demonstrate which is the better partner strategy, endocrine therapy or chemotherapy, to combine with anti-HER2 therapy as the first-line management of hormone receptor (HR)-positive (HR(+)) and HER2-positive (HER2(+)) metastatic breast cancer (MBC). We wished t...

Descripción completa

Detalles Bibliográficos
Autores principales: Hua, Xin, Bi, Xi-Wen, Zhao, Jian-Li, Shi, Yan-Xia, Lin, Ying, Wu, Zhi-Yong, Zhang, Yuan-Qi, Zhang, Le-Hong, Zhang, An-Qing, Huang, Heng, Liu, Xin-Mei, Xu, Fei, Guo, Ying, Xia, Wen, Hong, Ruo-Xi, Jiang, Kui-Kui, Xue, Cong, An, Xin, Zhong, Yong-Yi, Wang, Shu-Sen, Huang, Jia-Jia, Yuan, Zhong-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377763/
https://www.ncbi.nlm.nih.gov/pubmed/34810217
http://dx.doi.org/10.1158/1078-0432.CCR-21-3435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377763/
https://www.ncbi.nlm.nih.gov/pubmed/34810217
http://dx.doi.org/10.1158/1078-0432.CCR-21-3435

Ejemplares similares